Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline receives recommendations for cancer treatments

GlaxoSmithKline receives recommendations for cancer treatments

22nd February 2010

GlaxoSmithKline has received the backing of the European Medicines Agency’s (EMEA’s) Committee for Medicinal Products for Human Use (CHMP) for two potentially promising new cancer drugs.

The CHMP has endorsed both the breast cancer drug Tyverb and the kidney cancer treatment Votrient, both of which are orally administered, for approval by the EMEA.

Both of these treatments have undergone a series of clinical trials, from which the company was able to collate evidence of their safety and effectiveness.

Eddie Gray, president of GlaxoSmithKline Pharmaceuticals in Europe, welcomed the number of positive recommendations the healthcare firm has been granted by the CHMP in recent months.

This includes the positive opinion received last month for Arzerra, its treatment for refractory chronic lymphocytic leukaemia.

Mr Gray said: “We are proud that the rapid pace of our development programme is delivering products that may make a difference for those patients who continue to try and overcome these two types of cancers.”

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.